📋 Tender Overview
Guiding Multi-Modal Therapies Against Mrd By Liquid Biopsies - Guide.Mrd
Advancing Personalised Cancer Therapytumours Release Fragments Of Dna Into The Bloodstream While They Grow And Divide. This Circulating Tumour Dna (Ctdna) Can Be Detected And Analysed In Clinical Practice, Usually Via Liquid Biopsy, To Provide Valuable Information About The Tumour~S Genetic Characteristics. Funded By The Horizon Programme, The Guide.Mrd Project Aims To Standardise And Validate Ctdna Diagnostics For Clinical Use. The Project Will Involve Regulatory Authorities To Provide Evidence-Based Recommendations And Guidelines For Utilising Ctdna Tests To Guide Multi-Modal Therapies In Cancer Patients Following Surgery. Protocols For Ctdna Analysis And Interpretation Across Different Cancer Types Will Support Personalised Treatments For Enhanced Patient Outcomes.
Funded Under
Health
Total Cost
€ 34 452 565,00
Eu Contribution
€ 17 660 955,00
Coordinated By
Universitaetsklinikum Hamburg-Eppendorf
Germany
